Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETHEMA LPA 2005: Risk-Adapted Treatment for Acute Promyelocytic Leukemia
NCT00408278Phase 4Completed
- Sponsor
- Fundación PETHEMA
- Start
- Jul 2005
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 4, open-label trial of cytarabine in acute promyelocytic leukemia (APL) (2 arms), sponsored by Fundación PETHEMA. Primary endpoints: Efficacy and Toxicity of Risk-Adapted Protocol at 1 year, Event-Free Survival at 1 year and 5 more. Started Jul 2005; status: completed.
02
Drugs
cytarabine
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT00408278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00408278.